Orient Pharma Co., Ltd. (TPEX:4166)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
26.35
+0.35 (1.35%)
Apr 28, 2026, 1:30 PM CST
-13.89%
Market Cap 5.80B
Revenue (ttm) 1.40B
Net Income (ttm) 208.44M
Shares Out 223.04M
EPS (ttm) 0.90
PE Ratio 28.74
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 130,650
Average Volume 244,040
Open 25.90
Previous Close 26.00
Day's Range 25.90 - 26.50
52-Week Range 22.30 - 40.00
Beta 0.13
RSI 54.51
Earnings Date Aug 13, 2026

About Orient Pharma

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan. [Read more]

Sector Healthcare
Founded 2008
Employees 173
Stock Exchange Taipei Exchange
Ticker Symbol 4166
Full Company Profile

Financial Performance

In 2025, Orient Pharma's revenue was 1.40 billion, an increase of 14.52% compared to the previous year's 1.22 billion. Earnings were 208.44 million, an increase of 94.12%.

Financial Statements

News

There is no news available yet.